Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 2Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Recurrence 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 27Rituximab 20Etoposide 14Cytarabine 13Melphalan 11Vincristine 10fludarabine 9Prednisone 9Doxorubicin 9Busulfan 8Peripheral Blood Stem Cell Transplantation 7Radiotherapy 6Filgrastim 6Cyclosporine 6Bendamustine Hydrochloride 6fludarabine phosphate 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Mycophenolic Acid 5Cisplatin 5tositumomab I-131 4ibritumomab tiuxetan 4Ifosfamide 4Dexamethasone 4Carmustine 4relmacabtagene autoleucel 3Thiotepa 3Indium 3Immunotherapy, Adoptive 3Gemcitabine 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Non-Hodgkin × zanubrutinib × Clear all
NCT05200312 2022-03-11

ZR2-CHOP

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
36 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡